Importance of Non-Patent Exclusivities in the Life-Cycle Management of Pharmaceuticals
The Canadian Intellectual Property Review (CIPR) is a double-blind peer reviewed journal. It is sent to over 1,800 IPIC members at no cost and can be purchased by non-members for a fee. If you would like to browse the articles included in the CIPR, please consult our database below.
Any author, member or non-member can submit an article for consideration in the CIPR. The CIPR Editorial Board welcomes both short pieces (2,000 to 5,000 words) that may be included in the Notes section of the issue or longer, more in-depth articles. The maximum length of articles, including references, is 20,000 words. Articles may be submitted in French or English. Each article should be accompanied by a 150-word abstract.
All submissions undergo a double-blind review process: the reviewers are not given the authors' identities and the identities of the reviewers are shielded from the authors. Additionally, articles submitted must be original and must not have been previously published elsewhere.
If you would like to submit an article for an upcoming issue of the CIPR please contact admin@ipic.ca.
Canadian Intellectual Property Review
Share
Importance of Non-Patent Exclusivities in the Life-Cycle Management of Pharmaceuticals
Issue: Volume 27 no 1
Author(s): Serge Lapointe and Julie-Anne Archambault
Abstract:
In order to provide a fair balance between the need for new pharmaceuticals and the need to provide medicine at a reasonable price to the general public, governments have put in place different mechanisms of protection and exclusivities. While patenting is probably the oldest and most common form of protection, other forms of exclusivities exist. Some forms of protection are especially suited to research-based pharmaceutical companies’ needs, while others are more in line with the needs of generic companies. This article discusses the use of alternative, non-patent forms of protection, otherwise known as “marketing exclusivity,” “data protection” or “data exclusivity,” and “patent term extension.” This article defines and establishes the span of such protections in different jurisdictions, including the United States, Canada, Europe, and Japan, by analyzing and comparing the various existing regulations. It is critical in the life-cycle management of new drugs that pharmaceutical stakeholders be aware of, fully understand, and properly use these additional forms of protection to maximize their return on investment.
